Our pre-clinical studies have shown that inhibition of the CaMKII‒MK2 pathway ameliorates all of these processes [7, 9], and germline deletion of MK2 in Ldlr-/- mice was shown to suppress atherosclerosis, but effects on plaque stability and glucose metabolism was not reported in that study [14]. This evidence concerns the gene MAPKAPK2 and atherosclerosis.